China Pharma Holdings, Inc.
CPHI · AMEX
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.03 | -0.00 | -0.99 | 0.33 |
| FCF Yield | 4.82% | -0.16% | -0.08% | -0.09% |
| EV / EBITDA | -47.96 | -0.00 | -58.47 | -114.09 |
| Quality | ||||
| ROIC | -6.14% | -6,768,257.11% | -9.91% | -9.61% |
| Gross Margin | -8.48% | -11.97% | -4.91% | -47.23% |
| Cash Conversion Ratio | 0.36 | -0.55 | 0.07 | -0.19 |
| Growth | ||||
| Revenue 3-Year CAGR | 4,497.35% | -17.90% | -20.22% | -17.63% |
| Free Cash Flow Growth | 302.58% | -303.71% | 8.89% | 62.57% |
| Safety | ||||
| Net Debt / EBITDA | -15.55 | -0.00 | -3.97 | -8.51 |
| Interest Coverage | -23.84 | -27,066,433.57 | -40.23 | -31.81 |
| Efficiency | ||||
| Inventory Turnover | 0.66 | 642,951.35 | 0.52 | 0.65 |
| Cash Conversion Cycle | 120.68 | 0.00 | 176.72 | 150.44 |